Arrowhead Pharmaceuticals, Inc. (ARWR) Discusses SHASTA-3 and SHASTA-4 12-Month Results for Plozasiran in Severe Hypertriglyceridemia August 31, 2026 8:00 AM EDT
Company Participants
Vincent Anzalone – Head of Investor Relations & VP
Jennifer Hellawell – Vice President of Clinical Development
Andy Davis – SVP of Cardiovascular & Head of Metabolic Franchise
James Hamilton – Chief Medical Officer and Head of R&D
Conference Call Participants
Gerald F. Watts
Børge Nordestgaard
Lut Ming Cheng – JPMorgan Chase & Co, Research Division
Michael Ulz – Morgan Stanley, Research Division
Maurice Raycroft – Jefferies LLC, Research Division
Prakhar Agrawal – Cantor Fitzgerald & Co., Research Division
Jason Gerberry – BofA Securities, Research Division
Presentation
Operator
Good morning, everyone, and welcome to the Arrowhead Pharmaceuticals Investor Webcast. [Operator Instructions] As a reminder, this call is being recorded, and a replay will be made available on the Arrowhead website following the conclusion of the event. I’d now like to turn the call over to Vince Anzalone, Senior Vice President of Finance and Investor Relations at Arrowhead Pharmaceuticals.
Vincent Anzalone
Head of Investor Relations & VP
Thank you, Tara, and thanks, everybody, for joining us today. We’re excited to present the data that we presented yesterday at the European Society of Cardiology in Munich for what we think is groundbreaking data from the SHASTA-3 and 4 studies of plozasiran.
So before we start, I just want to make sure everybody knows that we will be making forward-looking statements today. So refer to our SEC filings for risk factors. I also want to remind people that the SHTG indication has not been reviewed or approved by any regulatory authorities around the world, so it should be considered investigational. And the results here are preliminary. So they should not be used with — for HCPs or patients or in product promotion in any way. This is an investor-focused communication today.
